Tag: ASH:

TUESDAY, Dec. 8, 2020 — Self-reported patient race is the most important factor associated with poorer survival in patients with acute myeloid leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology, held virtually from Dec. 5 to 8. Bhavana Bhatnagar, D.O., from The Ohio State University Comprehensive

A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study being presented by Alfred L. Garfall, MD, an assistant professor of Medicine in the division of Hematology-Oncology in the